Yeah but, no but ... [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2012-08-07 17:14 (4702 d 06:23 ago) – Posting: # 9047
Views: 14,743

Dear Detlew!

❝ ❝ […] If one follows Method B, IMHO a posteriori simulations are not necessary if the study was planned with a n1 corresponding to max. αemp.. That would mean that we are already on ‘top of the ridge’.


❝ Beeing on the ‘top of the ridge’ would mean IMHO that we are practically working with alpha1,2 = 0.0294.


Exactly. That’s what I mean by “if the study was planned with a n1 corresponding to max. αemp. above.

❝ Another rather clear message of this nice picture: Don't use n1 as low as 12 ('internal pilot' in the usual understanding of many sponsors) if the anticipated CV is >25%.


Yep. I was always preaching (though in the context of ‘classical’ pilot studies) against too small sample sizes if the anticipated CV is large.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,674 registered users;
18 visitors (0 registered, 18 guests [including 14 identified bots]).
Forum time: 23:38 CEST (Europe/Vienna)

Medical researches can be divided into two sorts:
those who think that meta is better and those
who believe that pooling is fooling.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5